OTCPK:RAONF (Australia)
Business Description
Race Oncology Ltd
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Compare
Compare
Traded in other countries / regions
RAC.Australia
•
RAONF.USA
Description
Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.98 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.7 | |||||
| 3-Year EPS without NRI Growth Rate | 20.1 | |||||
| 3-Year FCF Growth Rate | 14.2 | |||||
| 3-Year Book Growth Rate | -2.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -44.23 | |||||
| 12-1 Month Momentum % | -46.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 49.05 | |||||
| Quick Ratio | 49.05 | |||||
| Cash Ratio | 47.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.37 | |||||
| ROA % | -41.46 | |||||
| ROIC % | -234.74 | |||||
| ROC (Joel Greenblatt) % | -2187.02 | |||||
| ROCE % | -45.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.92 | |||||
| Price-to-Tangible-Book | 8.53 | |||||
| EV-to-EBIT | -42.71 | |||||
| EV-to-EBITDA | -44.56 | |||||
| EV-to-FCF | -46.45 | |||||
| Price-to-Net-Current-Asset-Value | 8.53 | |||||
| Price-to-Net-Cash | 9.06 | |||||
| Earnings Yield (Greenblatt) % | -2.34 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with OTCPK:RAONF
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.048 | ||
| Beta | 0 | ||
| Volatility % | 44.45 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.007668 | ||
| 20-Day SMA ($) | 1.45 | ||
| 12-1 Month Momentum % | -46.1 | ||
| 52-Week Range ($) | 1.45 - 3.12 | ||
| Shares Outstanding (Mil) | 159.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Race Oncology Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||